Supplementary granulocyte macrophage colony‐stimulating factor to chemotherapy and programmed death‐ligand 1 blockade decreases local recurrence after surgery in bladder cancer
Author:
Affiliation:
1. Department of Urology Nara Medical University Nara Japan
2. Department of Psychiatry Nara Medical University Nara Japan
3. Department of Diagnostic Pathology Nara Medical University Nara Japan
Publisher
Wiley
Subject
Cancer Research,Oncology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14158
Reference42 articles.
1. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
2. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
3. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209
4. Surgical Factors Influence Bladder Cancer Outcomes: A Cooperative Group Report
5. Clinical Outcome of a Large-Scale Multi-Institutional Retrospective Study for Locally Advanced Bladder Cancer: A Survey Including 1131 Patients Treated during 1990–2000 in Japan
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis;Frontiers in Immunology;2024-02-06
2. Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer;Therapeutic Advances in Medical Oncology;2024-01
3. Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors;Cancer Biology & Medicine;2023-11-06
4. Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer;Cancer Science;2022-11-30
5. Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?;Seminars in Cancer Biology;2022-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3